Shares of Decoy Therapeutics (DCOY) surged +124% to $12.38 in pre-market trading Monday, an extraordinary reversal for a stock that closed Friday at just $5.52 and had drifted lower all week. The catalyst: traders repricing a pair of capital-raising moves that initially spooked the market but now signal that this tiny, pre-revenue biotech may have bought itself time to survive.
An Institutional Investor Bet $21 Million on a Company Worth $3 Million
On June 26, Decoy announced a private placement deal (known as a PIPE) with a single healthcare-focused institutional investor worth up to $21 million in potential proceeds. The deal delivers $3.5 million upfront at $5.91 per share, plus milestone-based warrants — the right to buy shares later — tied to Phase 1 and Phase 2a clinical trial results in Europe and the UK. For a company with a market cap of roughly $2.9 million , this is a transformative sum — if the milestones are hit.
Dilution Is Real, and It's Massive
As of June 9, Decoy had just 531,968 common shares outstanding; if all 808,000 registered shares under its S-1 are issued, they would represent about 60% of post-issuance shares, creating substantial dilution.
Half the net proceeds from those share sales must go toward redeeming its Series B Preferred Stock — debt-like obligations — not into the lab. That means existing shareholders absorb heavy dilution while much of the cash services old obligations.
No Revenue, No Drug, and $12.5 Million in Annual Losses
Decoy's operating income was -$12.6 million, net income was -$12.5 million, and it burned -$4.8 million in operating cash flow.
Its first Phase 1 clinical trial is targeted for 2027.
The company has just 11 employees. At today's inflated price, investors are paying a speculative premium for a drug platform that has never been tested in humans.
A Microcap Squeeze, Not a Fundamental Re-Think
The stock's pre-market explosion reflects the volatile dynamics of microcap names with tiny share floats — small amounts of buying can move prices dramatically. The PIPE offering closing is expected today, June 29 , meaning the deal's completion could either validate or deflate the rally. With net proceeds earmarked to advance its lead antiviral drug into the clinic , Decoy's real test is years away. Traders should treat this move as a liquidity event, not a verdict on the science.